Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE.

Lupus Erythematosus, Systemic Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01838694
• Other study ID #: IVXCpn001
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: April 17, 2013
• Last updated: September 4, 2015
• Start date: July 2013
• Est. completion date: August 2015

Study information

• Verified date: September 2015
• Source: Invion, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The primary objective of the study is to evaluate the safety, tolerability, and efficacy of 4 weeks intravenous treatment with Cpn10 in subjects with mild to moderate active SLE.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 29
• Est. completion date: August 2015
• Est. primary completion date: August 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria (ALL must be met):

To be entered on study, subjects must meet the following criteria:

1. Male or female

2. Age 18 - 75 years

3. Patients fulfilling at least 4 criteria for SLE as defined by the American College of Rheumatology (ACR)

4. Laboratory values as follows:

Documented ANA titer = 1:160 or positive anti-dsDNA antibodies at, or any time prior to screening (verifiable laboratory result)

5. Not pregnant or breast-feeding

6. If corticosteroids are required for disease stability prior to study entry, able to tolerate a stable dose of = 0.3 mg/kg/day of prednisone or equivalent for the duration of the study.

7. Agreement to use an effective form of contraception for the duration of the study.

8. Ability to understand and give consent.

9. Willing to participate and able to comply with the study requirements, procedures and visits.

Mild SLE only

10. Present with mild active SLE disease

Moderate SLE only

11. Present with active SLE disease based on SLE disease activity score (SLEDAI) =4 and =10

12. MCP-1 urinary level > 35 pg/ml

13. IL-6 serum level > 10 pg/ml

14. Meets the American College of Rheumatology (ACR) conditions for "renal disorder" as one of the diagnostic criteria for SLE i.e.

1. Persistent proteinuria between 0.5 and 1.0 grams per day or > than 3+ by dipstick OR

2. Cellular casts--may be red cell, hemoglobin, granular, tubular, or mixed

OR

15. Physician (Pathologist) diagnosis of lupus nephritis of no greater severity than:

1. Class I - Minimal mesangial lupus nephritis, OR

2. Class II - Mesangial proliferative lupus nephritis, in accordance with the International Society of Nephrology (ISN) and the Renal Pathology Society (RPS) 2003 histological classification.

With diagnosis made = 6 months prior to study commencement.

16. If inclusion criteria #15 is met, subject must be receiving stable Standard of Care, including hydroxychloroquine, treatment appropriate for class I-II nephritis.

Exclusion Criteria (NONE can apply):

1. Active severe SLE flare with central nervous system (CNS) and/or renal manifestations, pericarditis, active pleuritis, active peritonitis or other SLE manifestations requiring treatment not allowed by the study protocol within 4 weeks of screening

2. Pregnant or breast-feeding

3. Lack of peripheral venous access.

4. History of cardiovascular disease. An acute cardiovascular event within 12 months of study entry, including arterial or venous thrombosis (blood clots).

5. Requirement for a stable dose of corticosteroid >0.3 mg/kg/day of prednisone or equivalent.

6. Active therapy with human or murine monoclonal antibodies (i.e. belimumab), within 2 months of study entry.

7. Any experimental therapy within 3 months of study entry.

8. Therapy with cyclophosphamide p.o or parenteral; pulse methylprednisolone or IVIG within 4-6 weeks.

9. Subjects being treated with sulfonylureas.

10. Subjects with any the following laboratory abnormalities: serum creatinine >3.0 mg/dL, WBC <3,500/µL, ANC <3,000/µL, absolute lymphocyte count =500/µL, Hgb <8.0 g/dL, platelets <50,000/µL, ALT and/or AST >1.5 x upper limit of normal (ULN), alkaline phosphatase >1.5 ULN.

11. Personal or psychiatric condition that precludes the subject being able to comply with the study requirements or understand and agree to the informed consent process.

12. Recent systemic bacterial, fungal, viral, or parasitic infections. Have required management/treatment or hospitalization for any infection within the last 4 weeks before screening.

13. History of malignancy - except completely excised basal cell carcinoma.

14. Impaired hepatic function

15. Body weight of 260lbs/120kg or more (BMI > 35)

16. History of tuberculosis (TB) or active, continuing treatment for TB

17. History of or current alcohol or substance abuse

Mild SLE only

18. Active lupus nephritis and/or severe renal impairment (estimated or measured GFR < 50% predicted for age and gender)

Moderate SLE only

19. Subjects with recently diagnosed lupus nephritis (diagnosis made <6 months prior to commencement of study

20. Subjects with active urinary sediment

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Lupus Erythematosus, Systemic

Intervention

Biological:
• Ala-Cpn10

Drug:
• Placebo

Locations

Country	Name	City	State
United States	Altoona Arthritis and Osteoporosis Center	Altoona	Pennsylvania
United States	Northwestern University School of Medicine	Chicago	Illinois
United States	Metroplex Clinical Research Center	Dallas	Texas
United States	Penn State Milton S. Hershey Medical Center	Hershey	Pennsylvania
United States	Abel Buchheim Pharmaceutical Research	Miami	Florida
United States	Hospital of the University of Pennsylvania	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Invion, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reduction from baseline serum Interleukin 6 (IL-6) levels at the end of active dosing, comparing treatment to placebo cohort.		4 weeks	No